AVDL vs LFCR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical while LFCR counters with relative strength in Valuation, Options & Structure. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus LFCR at 8.7x Forward P/E and -6.2% operating margin (-18.6% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against LFCR sits in CONSOLIDATION (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | LFCR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $241.5M | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 16.8x | 8.7x | Lower Multiple | LFCR |
| Forward P/E Ratio Valuation | 28.8x | 8.7x | Lower Multiple | LFCR |
| Revenue Growth (YoY) Growth | +54.9% | -18.6% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | -6.2% | Higher Margin | AVDL |
| Net Profit Margin Profitability | -0.1% | -66.8% | Higher Margin | AVDL |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -76.4% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 52% ($4โ$9) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 0.44ฮฒ ยท 9% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 58.2 / 100 (HOLD) | Higher Composite | AVDL |